Table 2.
Investigator Global Assessment (IGA) Score by Retrospective Review of Clinical Charts and Photographs and Patient Global Assessment of Treatment (PGA) Based on 5-Point Likert Scale
| Medium IGA Score T0 (Median) | Medium IGA Score T2 (Median) | Medium IGA Score T4 (Median) | Medium PVAS Score T0 (Median) |
Medium PVAS Score T2 (Median) | Medium PVAS Score T4 (Median) | Medium DLQI Score T0 (Median) | Medium DLQI Score T2 (Median) | Medium DLQI Score T4 (Median) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total patients | 20 | 3.35 (4) |
1.35 (2) |
0,4 (0) |
4.25 (4) |
2.25 (2) |
0,6 (0) |
19.25 (19) |
0 (0) |
0 (0) |
| Male (number) |
65% (13) |
2.46 (3) |
0.65 (2) |
0,2 (0) |
4.08 (4) |
2 (2) |
0.35 (0) |
20 (20) |
0 (0) |
0 (0) |
| Female (number) |
35% (7) |
3.28 (4) |
1.57 (2) |
0.57 (1) |
4.57 (4) |
2.43 (3) |
0.25 (1) |
17.86 (17) |
0 (0) |
0 (0) |
For IGA, we rated overall severity on a 0-to-4 scale as 0 1/4 clear, 1 1/4 almost clear, 2 1/4 mild, 3 1/4 moderate, and 4 1/4 severe. We considered treatment to be successful when lesions cleared or were almost cleared. Subjects were considered successfully treated if the erythema and scaling as well as investigator global assessment (IGA) scores decreased to 0 (or 1 if the baseline score was > or =3).